Stocks Health care ANNX
NASDAQ · Health careAnnexon, Inc. (ANNX)
It posted a net loss of $199M. In fiscal 2025 capital spending exceeded operating cash flow by $186.5M. At September 30, 2026 it held $102.4M in cash against $49.3M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 9, 2026.
Key facts about Annexon, Inc.
- Net worth
- Annexon, Inc. has a market value (market cap) of $801.9M at the latest share price, and shareholders' equity of $142.8M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $186.4M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 9, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Annexon, Inc.'s next report is expected around March 29, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Annexon, Inc. does
Annexon, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ANNX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$206.7M | -$1.34 | -$186.5M |
| 2024 | n/a | -$138.2M | -$1.01 | -$118M |
| 2023 | n/a | -$134.2M | -$1.77 | -$121.3M |
| 2022 | n/a | -$141.9M | -$2.60 | -$122.8M |
| 2021 | n/a | -$130.3M | -$3.40 | -$107.8M |
| 2020 | n/a | -$63.4M | -$4.15 | -$53.6M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Annexon, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026
- November 9, 2026
- November 5, 2026Passive stake changed SCHEDULE 13G/A
- August 12, 2026
- August 12, 2026
- August 10, 2026
- August 7, 2026Passive stake (5% or more) SCHEDULE 13G
- August 6, 2026Other event 8-K
- July 30, 2026
- July 27, 2026Passive stake changed SCHEDULE 13G/A
Insider trades
What the people running Annexon, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $99.8K worth of shares on the open market in the last 90 days and sold none.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 24, 2026 | Love DouglasPRESIDENT AND CEO, Director | Bought | 26,065 | $99.8K |
| June 11, 2026 | Yednock TedEVP & CHIEF INNOVATION OFFICER | Exercised options | 30,646 | $56.7K |
| May 28, 2026 | Satter Muneer ADirector | Boughtindirect | 613,497 | $3.3M |
| May 11, 2026 | Carson William H.Director | Bought | 8,000 | $46.2K |
| April 10, 2026 | Carson William H.Director | Bought | 8,000 | $49.6K |
| March 10, 2026 | Carson William H.Director | Bought | 8,000 | $45.4K |
| March 2, 2026 | Lew JenniferEVP & CHIEF FINANCIAL OFFICER | Sold | 5,565 | $30.2K |
| March 2, 2026 | Dananberg JamieCHIEF MEDICAL OFFICER | Sold | 5,820 | $31.6K |
Who owns ANNX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Fmr LLC13G, passive with 1 related filers | 11.9% | July 8, 2026 |
| Redmile Group, LLC13G, passive with 2 related filers | 9.9% | July 8, 2026 |
| Satter Muneer A13D, may seek influence | 7.2% | November 21, 2025 |
| Bvf Partners L P13G, passive with 9 related filers | 5.4% | May 15, 2026 |
Largest institutional holders
Insiders
9 insiders reported holding 11,685,822 shares in total, about $49.4M at the last price.
| Holder | Shares |
|---|---|
| Satter Muneer ADirector | 10,342,13410,342,134 held indirectly |
| Love DouglasPRESIDENT AND CEO, Director | 390,476 |
| Yednock TedEVP & CHIEF INNOVATION OFFICER | 184,807 |
| Overdorf MichaelEVP & CHIEF BUSINESS OFFICER | 182,625 |
| Artis Dean RichardEVP & CHIEF SCIENTIFIC OFFICER | 180,093 |
| Lew JenniferEVP & CHIEF FINANCIAL OFFICER | 170,700 |
| Dananberg JamieCHIEF MEDICAL OFFICER | 123,582 |
| Carson William H.Director | 78,405 |
| Choi JungDirector | 33,00033,000 held indirectly |
Questions about ANNX
What does Annexon, Inc. do?
Annexon, Inc. is a company in the Health care sector, listed on NASDAQ as ANNX. Its shares trade on NASDAQ under the ticker ANNX.
What is Annexon, Inc.'s net worth?
Annexon, Inc. has a market value (market cap) of $801.9M at the latest share price, and shareholders' equity of $142.8M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Annexon, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $199M.
When did Annexon, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 9, 2026. It covers the period to September 30, 2026.
When is Annexon, Inc.'s next earnings report?
Annexon, Inc.'s next report is expected around March 29, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare ANNX with
Follow ANNX
Get an email when Annexon, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Annexon, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.